UNSPSC 51385801: Ampiroxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H21N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PV32JZB1J, chemically known as carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl)oxy)ethyl ester, s,s-dioxide but generally known as ampiroxicam, which bears US NIH Compound Identifier 2176. European Medicines Agency schedules Ampiroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05488MIG.

UNSPSC 51385801 Ampiroxicam is a Commodity code that nominally covers a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code does not reflect pharmaceutical purchases aligned with the code's abstract name. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking to procure naloxone and drug deactivation systems—products unrelated to ampiroxicam—suggesting either a tagging mismatch in the source data or a broad misapplication of the code to emergency medical and substance-abuse-response equipment. The single visible opportunity targets community health initiatives and does not reflect typical pharmaceutical procurement in the scope the code nominally describes.

Seminole County, Florida is the sole identified recent issuer under this code. The IFB called for 1,900 units of naloxone and 800 safe drug deactivation systems with annual, quarterly deliveries to the Seminole County Community Health Building in Sanford. The response deadline was July 26, 2023, though the solicitation was posted on June 30, 2026—a date inconsistency in the source. Vendors were required to submit bids electronically, include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify requirements and drug-free workplace certification. The contract was structured with an initial two-year term and one-year renewal option on a fixed-fee basis. No explicit set-aside designations or budget ranges were stated. The code shows minimal recent activity at the state and local level, and the single visible opportunity appears misaligned with the code's pharmaceutical scope.